Preclinical studies of methylthioadenosine for the treatment of multiple sclerosis

Multiple Sclerosis

Volumn 16, Issue 9, 2010, Pages 1102-1108

  Moreno, B ^a   Fernandez Diez, B ^a   Di Penta, A ^a   Villoslada, P ^a  

^a HOSPITAL CLÍNIC   (Spain)

Author keywords

methylthioadenosine; multiple sclerosis; oral; pharmacokinetics; preclinical development

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BETA INTERFERON; GLATIRAMER; IMMUNOLOGICAL ADJUVANT; IMMUNOMODULATING AGENT; LIVER ENZYME; METHYLTHIOADENOSINE; MYELIN OLIGODENDROCYTE GLYCOPROTEIN; UNCLASSIFIED DRUG;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IMMUNIZATION; MOUSE; MULTIPLE SCLEROSIS; NONHUMAN; RAT; SPRAGUE DAWLEY RAT;

ADENOSINE; ADMINISTRATION, ORAL; ANIMALS; CHEMISTRY, PHARMACEUTICAL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; DRUG THERAPY, COMBINATION; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; FEMALE; GLYCOPROTEINS; HALF-LIFE; IMMUNOLOGIC FACTORS; INJECTIONS, INTRAPERITONEAL; INTERFERON-BETA; MICE; MICE, INBRED C57BL; PEPTIDE FRAGMENTS; PEPTIDES; RATS; RATS, SPRAGUE-DAWLEY; THIONUCLEOSIDES;

EID: 77956323733     PISSN: 13524585     EISSN: None     Source Type: Journal    
DOI: 10.1177/1352458510375968     Document Type: Article

References (14)

1. Avila MA, Garcia-Trevijano ER, Lu SC, et al. Methylthioadenosine. Int J Biochem Cell Biol 2004 ; 36: 2125-2130.
2. Moreno B., Hevia H., Santamaria M., et al. Methylthioadenosine reverses brain autoimmune disease. Ann Neurol 2006 ; 60: 323-334.
3. Lawson BR, Manenkova Y., Ahamed J., et al. Inhibition of transmethylation down-regulates CD4 T cell activation and curtails development of autoimmunity in a model system. J Immunol 2007 ; 178: 5366-5374.
4. Hauser SL and Oksenberg JR The neurobiology of multiple sclerosis: genes, inflammation, and neurodegeneration. Neuron 2006 ; 52: 61-76.
5. Bhat R. and Steinman L. Innate and adaptive autoimmunity directed to the central nervous system. Neuron 2009 ; 64: 123-132.
6. Palacios R., Goni J., Martinez-Forero I., et al. A network analysis of the human T-cell activation gene network identifies JAGGED1 as a therapeutic target for autoimmune diseases. PLoS ONE 2007 ; 2: e1222.
7. Wang Y., Feng D., Liu G., et al. Gamma-aminobutyric acid transporter 1 negatively regulates T cell-mediated immune responses and ameliorates autoimmune inflammation in the CNS. J Immunol 2008 ; 181: 8226-8236.
8. Stüve O., Yousself S., Weber MS, et al. Immunomodulatory synergy by combination of atorvastatin and glatiramer acetate in treatment of CNS autoimmunity. J Clin Invest 2006 ; 116 (4). 1037-1044.
9. Giuliani F., Fu SA, Metz LM and Yong VW Effective combination of minocicline and interferon-beta in a model of multiple sclerosis. J Neuroimmunol 2005 ; 165: 83-91.
10. Compston A. and Coles A. Multiple sclerosis. Lancet 2008 ; 372: 1502-1517.
11. Hemmer B. and Hartung HP Toward the development of rational therapies in multiple sclerosis: what is on the horizon? Ann Neurol 2007 ; 62: 314-326.
12. Villoslada P., Moreno B., Melero I., et al. Immunotherapy for neurological diseases. Clin Immunol 2008 ; 128: 294-305.
13. Stramentinoli G. and Gennari F. Adenosine derivatives of anti-inflammatory and analgesic activity, and therapeutic compositions which contain them as their active principle. US 1984 ; 4, 454, 122: 20-33.
14. Moratti E. Pharmaceutical compositions containing 5-2-deoxy-5-2- methylthioadenosine s-adenosylmethionine and their salts for reducing seborrhea. US 1998 ; 5, 753, 213: 12-22.